BIT’s 9th Annual World Congress of Vaccine-2017
★ Scientific Program

BIT’s 9th Annual International Congress of


Vaccine-2017

Theme:New Technologies, New Vaccines
Time: March 29-31, 2017
Venue: Beijing, China


 

 

 

Plenary Forum & Keynote Forum of ICA-2017 & WCV-2017
Day 1: Morning, Wednesday, March 29, 2017
Time: 08:30-12:10
Venue: Beijing, China
Operator: Dr. Yong Qian, Chairman, BioMedicure Group, USA and China
Time FaceOn Speeches and Speakers Org. Logo
09:00-09:10 Operator's Introduction
09:10-09:35   Title: Cancer Immunotherapy: Deliver the Promise 
Dr. Weikang Tao, Vice President and CEO of R&D Center, Jiangsu Henrui Medicine Co., Ltd., China
 
09:35-10:00 Title: Xenogeneic Antibody Based Immunotherapy: Progress and Possibilities
Dr. Madi Madiyalakan, 
CEO, Quest PharmaTech Inc., Canada
10:00-10:25 Title: Conducting MAB trials in China: opportunities and challenges
Dr. Dan Zhang,
Chairman and CEO, Fountain Medical Development Ltd. China
10:25-10:40 Title: Genomic Neo-antigen-based Acquired-immunity Platform
Dr. Yong Qian, Chairman,
BioMedicure Group, USA and China
10:40-11:00 Coffee Break
11:00-12:00 High-Level Talks with Entrepreneurs
12:00-13:30 Lunch

 

 

Pipeline 1: Vaccine R & D and New Technologies

 

 

Session 101: Vaccine R & D and New Technologies (Part 1)


Day 1: Afternoon, Wednesday, March 29, 2017
Time: 13:30-17:10
Venue: Beijing, China

Chair: Dr. Michel Klein, CSO, BravoVax, Wuhan, China
Co-Chair: Dr.Rajesh K. Gupta, Co-Owner & Principal Consultant, Biologics Quality & Regulatory Consultants, LLC, USA
13:30-13:35 Chair’s Introduction
13:35-14:00

Keynote speech
Title:
Building Quality during Manufacture of Vaccines – Quality by Design (QbD), Product Life Cycle and Modern Technologies/Methods

Dr. Rajesh K. Gupta, Co-Owner & Principal Consultant, Biologics Quality & Regulatory Consultants, LLC, USA

14:00-14:25

Title: Vaccinomics in the Next Century
Dr. Michel Klein,
CSO, BravoVax, Wuhan, China

14:25-14:50

Title: QS-21: A Potent Vaccine Adjuvant
Dr. Daming Zhu,
Head of Quality Control Unit, NIAID/NIH, USA

14:50-15:15 Title: Novel Adjuvant L-Pampo and Development of Improved HBV Vaccines
Dr. Jung Sun Yum ,
Executive Director, CHA Vaccine Institute, Korea
15:15-15:30 Coffee Break
15:30-15:55 Title: Online Measurements of Viable and Total Cell Densities
Mr. Jochen Uhlenküken,
Business Development Manager, Hamilton Bonaduz AG, Switzerland
15:55-16:20

Title: Balance between Crystalline and Amorphous Excipients in Lyophilization and Spray drying Formulation Development
Dr. Tom H Jin,
Senior Scientist, IDT Biologika, USA

16:20-16:45

Title: New Technologies on the Development of Diagnostic Tools and Vaccine Discovery for Human Parasites
Dr. Kokouvi Kassegne,
Assistant Professor, National Institute of Parasitic Diseases, China CDC, China

 

Session 102: Vaccine R & D and New Technologies (Part 2)

Day 2: Morning, Thursday, March 30, 2017
Time: 10:30-12:15
Venue: Beijing, China

Chair: Dr. Tom H Jin, Senior Scientist, IDT Biologika, USA
10:30-10:35 Chair’s Introduction
10:35-11:00

Title: Age to End Dreadful Diseases (HIV, Malaria, TB, Cancer and More): A Theory of Intact or Protected Complement (IPC) Immunity
Dr. Tom H Jin,
Senior Scientist, IDT Biologika, USA

11:00-11:25

Title: Development of Novel Vaccines for Major Unmet Needs
Dr. Luis H. Martin, CEO, Pan-Provincial Vaccine Enterprise Inc., Canada

11:25-11:50

Title: Serotype Distribution and Penicillin Resistance of Streptococcus Pneumoniae in Kuwait: A Ten-Year Study of Impact of Pneumococcal Conjugate Vaccines
Dr. Eiman M A Mokaddas, Professor, Kuwait University, Kuwait

11:50-12:15 Title: The Development of Typhoid Conjugate Vaccines
Dr. Viliam Pavliak, Head of Vaccine Development, International Vaccine Institute, Korea

 

 

Pipeline 2: Human Vaccines for Major Infectious Diseases

 

Session 201: Human Vaccines for Major Diseases

Day 2: Afternoon, Thursday, March 30, 2017
Time: 13:30-17:10
Venue: Beijing, China

Chair: Dr. Armando Zuniga, CSO, Virometix AG, Switzerland
13:30-13:35 Chair’s Introduction
13:35-14:00

Title:Synthetic Virus-Like Particles (SVLPs) for the Development of Peptide-based Cancer Vaccines
Dr. Armando Zuniga,
CSO, Virometix AG, Switzerland

14:00-14:25

Title: Targeted Vaccination and Intrinsic Adjuvant Function: Next Generation Checkpoint Control
Dr. Geert. C. Mudde, Founder and CSO, OncoQR ML GmbH, Austria

14:25-14:50

Title: Next Generation Influenza Vaccines: Challenges and Recent Developments
Dr. Yuri M. Vasiliev,
Deputy Director for Science, St. Petersburg Research Institute for Vaccines and Sera, Russia

14:50-15:15 Title:  TB Vaccines:  Challenges and Approaches
Ms. Molly (Miao) Zhang, Project Coordinator, Aeras, China
15:15-15:30 Coffee Break
15:30-15:55 Title:The Impact of the Emerging Diseases In HIV Infection. Can We Prevent Them
Dr. Gustavo A. Echenique, Head of Infectious Diseases, Tropical and Infectious Diseases Unit “Nuestra Señora del Rosario” Clinic, Argentina
15:55-16:20

Title: Clinical Study of Cancer Vaccine-points to Consider in Trial Design
Dr. Lei Zhang, President, Biologicure Ltd., USA

 

 Pipeline 3: Veterinary Vaccines

 

 

Session 301: Veterinary Vaccines
Day 3: Morning, Friday, March 31, 2017
Time: 08:30-10:30
Venue: Beijing, China

Chair: Dr. Andrew A. Potter, CEO, Vaccine and infectious Disease Organization-International Vaccine Centre (VIDO-InterVac), Canada
08:30-08:35 Chair’s Introduction
08:35-09:00

Title: The Application of Three Antigenic Formulas Contaning Selected Recombinant Outer Membrane Proteins and LPS Core From Gram Negative Bacteria in Dairy Calves
Dr. Tadeusz Stefaniak,
Professor, Wroclaw University of Environmental and Life Sciences, Poland

09:00-09:25

Title:The Evaluation of Three Subunit Vaccines Formulas Containing Recombinant Outer Membrane Proteins and LPS Core Conjugate in Piglets
Ms. Anna Rzasa, Professor, Wroclaw University of Environmental and Life Sciences, Poland

09:25-09:50

Title: Vaccines for Foot and Mouth Disease (FMD) Specific Prevention in Farm Animals. Review of Preparations Manufactured in FGBI “ARRIAH”
Dr. Artem Metlin, Deputy Director, Federal Centre for Animal Health, Russia

09:50-10:15

Title: Recombinant NDV Expressing Cytokines or FliC Confers a Quick Immune Response Against NDV Challenge and Resistance to Maternal Antibody
Dr. Jiechao Yin, Northeast Agricultural University, China

10:15-10:30 Coffee Break
10:30-10:55  Title: Modelling and Optimizing Alternating Tangential Flow Filtration for Perfusion Cellculture
Dr. William J. Kelly,
Professor, Villanova University, USA
10:55-11:20 Title: Technology Innovations for Large Scale Cell Expansion
Dr. Huadong Liu,
Field Application Scientist, Corning Life Sciences, China

 

China Local Time
Days to Go!
Concurrent Congress

ICA-2017
Operating Organizations
Official Travel Agency
BIT’s Upcoming Events
Contact Us

Add: East Area, F11, Building 1, Dalian Ascendas IT Park, 1 Hui Xian Yuan, Dalian Hi-tech Industrial Zone, LN 116025, China]
Tel: 0086-411-84799609, Fax: 0086-411-84796897
Copyright © 2015-2016 BIT Congress Inc.